Continue with FacebookLooking to list your PhD opportunities? Log in here.
alzheimer PhD Projects, Programs & Scholarships
We have 69 alzheimer PhD Projects, Programs & Scholarships
PhD saved successfully
The application of artificial intelligence in the assessment of balance and gait for the patients with Alzheimer's Disease and the implication in the diagnosis and rehabilitation
Alzheimer’s disease is widely happened for the mid-aged and elderly. The prevalence of Alzheimer’s disease will be increased in the future. Read more
Determining brain glycosylation in ageing and Alzheimer’s disease
Research Group:
Pharmacology and Experimental Therapeutics
Increasing age is associated with lower levels of cognitive performance; concomitant with this is a decrease in brain glucose metabolism. Read more
ERK5 MAPK signalling in Alzheimer’s disease
Research Group:
Pharmacology and Experimental Therapeutics
Neurodegenerative diseases have devastating effects on individuals’ lives and our society, with no effective treatments available. Read more
Last chance to apply
Precision Medicine DTP – The synaptic basis of Cognitive reserve in Alzheimer's disease
Research Group:
Centre for Discovery Brain Sciences
Background. Traditionally, Alzheimer’s disease (AD) has been thought to be caused by progressive neuronal cell death (neurotoxic hypothesis). Read more
Protein Misfolding and Assembly of Amyloid-beta and lipid membrane interactions in Alzheimer’s Disease
Background. Worldwide, Alzheimer’s disease (AD) is the most common form of dementia. The disease is characterised by the accumulation of a small neuro-toxic peptide, amyloid-beta (Aβ) which forms fibrous plaques within the brain. Read more
Investigating the link between amyloid-β oligomers, neuroinflammation and cognitive deficits in preclinical models for Alzheimer’s Disease
Currently four out of the five pharmacological treatments used for Alzheimer’s disease (AD) are acetylcholinesterase inhibitors aimed at boosting the amount of acetylcholine in the brain, with the fifth being an N-methyl-D-aspartate (NMDA) receptor antagonist. Read more
Early detection of Alzheimer's disease using novel photonic technology
Research Group:
Physics of Life - Biological Physics and Biophysics
A major issue in the fight against Alzheimer’s disease (AD) is the need to identify patients in the earliest phase of the disease. Read more
Understanding how altered GABA signalling in the brain's master clock contributes to circadian rhythm disruption in Alzheimer's disease
Our circadian clock is one of the most important timing systems in our body, ensuring that neuronal activity throughout our CNS is appropriately aligned with our homeostatic, physiological, and behavioural needs across the day. Read more
Sex, Menopause and spontaneous Alzheimer’s disease
Applications are invited for a PhD studentship funded by the Faculty of Medicine and Health working under the supervision of Dr Matthew Pontifex (UEA), Prof Michael Müller (UEA) and Prof Tom Wileman (Quadram Institute) . Read more
Cognitive predictors of real-world patient and carer outcomes in Alzheimer’s disease.
Cognitive tests are an essential and effective tool in aiding clinicians in the identification of cognitive changes that herald a diagnosis of Alzheimer’s Disease. Read more
Screening of chemical libraries using iPS models for investigating the role of prion protein in Alzheimer’s disease
Background. AD has been identified as a protein misfolding disease (proteopathy). The disease is caused by accumulation of two major amyloids. Read more
Investigating the timing and causes of vascular dysfunction in Alzheimer’s disease
Rationale. Cerebrovascular damage accelerates and exacerbates cognitive decline and brain damage in Alzheimer's disease (AD)(1, 2). Read more
AI and Machine Learning for the diagnosis and monitoring of Parkinson’s and Alzheimer’s disease
Research Group:
Intelligent Systems and Nanoscience
The Department has long-standing research collaborations with hospitals and medical centres worldwide developing new approaches to the diagnosis and monitoring of neurological conditions, including Parkinson’s and Alzheimer’s. Read more
Understanding Amyloid Post-Translational Modification at the Nanoscale
Alzheimer’s disease is a fatal and incurable form of dementia, affecting 40 million people worldwide. Despite the high prevalence of Alzheimer’s disease, currently, there is no cure or biometric diagnostic test for it. Read more
